Deals
Gulf Sovereign Fund, Hedge Fund Tycoons Bankroll Biotech to Fight Aging
- Fundraising set to value Swiss company at nearly $400 million
- Rejuveron developing drugs to fight aging, extend lifespans
This article is for subscribers only.
Swiss biotech firm Rejuveron Life Sciences AG has attracted backing from sovereign fund Mubadala Investment Co. to help bankroll its development of drugs targeting the effects of aging, people familiar with the matter said.
Rejuveron has raised about $75 million from a series B funding round and convertible loan deal, the people said. Investors in the fundraising include Catalio Capital Management, the life sciences-focused firm backed by hedge fund billionaires Stan Druckenmiller and Alan Howard, the people said.